文献速递前列腺癌

MyProstateScore检测用于排除临床显著前列腺癌的验证研究

Use of the MyProstateScore Test to Rule Out Clinically Significant Cancer: Validation of a Straightforward Clinical Testing Approach.
PubMed 文献 · J Urol · 2020-10-20

本研究在活检初治男性中验证MyProstateScore(MPS)排除Grade Group≥2前列腺癌的阈值。训练队列确定MPS≤10对应约95%敏感性,在两个外部验证队列(学术977例、社区548例,共1525例)中,MPS≤10对Grade Group≥2癌的敏感性97%、阴性预测值98%,可避免33%不必要活检,仅遗漏3.0%的Grade Group≥2癌。

要点

  • MPS≤10在总体验证人群中对Grade Group≥2癌敏感性97%、阴性预测值98%。
  • MPS检测可避免33%不必要活检,仅遗漏3.0%的Grade Group≥2癌。
  • 在符合指南活检标准人群中,MPS≤10敏感性96%、阴性预测值97%。

核心结论

  • 在大型临床相关活检转诊人群中,MPS≤10对排除Grade Group≥2前列腺癌具有极高敏感性和阴性预测值。

研究设计与样本

  • 活检初治男性在直肠指检后、活检前提供尿液,使用锁定多变量模型计算MPS,仅含血清PSA、尿PCA3和尿TMPRSS2:ERG。
  • 训练队列确定MPS阈值,两个外部验证队列分别来自学术中心(977例,中位PSA 4.5,IQR 3.1-6.0)和社区(548例,中位PSA 4.9,IQR 3.7-6.8)。

主要发现

  • 总体验证人群1525例中,338例(22%)活检为Grade Group≥2癌。
  • MPS阈值10对Grade Group≥2癌敏感性97%、阴性预测值98%。
  • MPS检测可避免387例(33%)不必要活检,仅遗漏10例(3.0%)Grade Group≥2癌。
  • 符合指南标准(PSA 3-10,或PSA<3伴可疑直肠指检)的1242例中,MPS≤10敏感性96%、阴性预测值97%,可避免32%不必要活检,遗漏3.7%的Grade Group≥2癌。

关键数值与推荐

  • MPS≤10作为排除Grade Group≥2前列腺癌的阈值,在总体验证人群敏感性97%、阴性预测值98%。
  • 在符合指南活检标准人群中,MPS≤10敏感性96%、阴性预测值97%。

临床怎么用

  • 在PSA筛查后,可采用MPS≤10作为二次检测,减少更昂贵和有创的前列腺活检。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The MyProstateScore test was validated for improved detection of clinically significant (grade group ≥2) prostate cancer relative to prostate specific antigen based risk calculators. We sought to validate an optimal MyProstateScore threshold for clinical use in ruling out grade group ≥2 cancer in men referred for biopsy. MATERIALS AND METHODS: Biopsy naïve men provided post-digital rectal examination urine prior to biopsy. MyProstateScore was calculated using the validated, locked multivariable model including only serum prostate specific antigen, urinary prostate cancer antigen 3 and urinary TMPRSS2:ERG. The MyProstateScore threshold approximating 95% sensitivity for grade group ≥2 cancer was identified in a training cohort, and performance was measured in 2 external validation cohorts. We assessed the 1) overall biopsy referral population and 2) population meeting guideline based testing criteria (ie, prostate specific antigen 3-10, or <3 with suspicious digital rectal examination). RESULTS: Validation cohorts were prospectively enrolled from academic (977 patients, median prostate specific antigen 4.5, IQR 3.1-6.0) and community (548, median prostate specific antigen 4.9, IQR 3.7-6.8) settings. In the overall validation population (1,525 patients), 338 men (22%) had grade group ≥2 cancer on biopsy. The MyProstateScore threshold of 10 provided 97% sensitivity and 98% negative predictive value for grade group ≥2 cancer. MyProstateScore testing would have prevented 387 unnecessary biopsies (33%), while missing only 10 grade group ≥2 cancers (3.0%). In 1,242 patients meeting guideline based criteria, MyProstateScore ≤10 provided 96% sensitivity and 97% negative predictive value, and would have prevented 32% of unnecessary biopsies, missing 3.7% of grade group ≥2 cancers. CONCLUSIONS: In a large, clinically pertinent biopsy referral population, MyProstateScore ≤10 provided exceptional sensitivity and negative predictive value for ruling out grade group ≥2 cancer. This straightforward secondary testing approach would reduce the use of more costly and invasive procedures after screening with prostate specific antigen.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Tosoian JJ, Trock BJ, Morgan TM, et al. Use of the MyProstateScore Test to Rule Out Clinically Significant Cancer: Validation of a Straightforward Clinical Testing Approach. J Urol. 2020. PMID: 33080150. doi:10.1097/JU.0000000000001430

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。